These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 12606463)

  • 1. Administration of moderate and high doses of gonadotropins to female rats increases ovarian vascular endothelial growth factor (VEGF) and VEGF receptor-2 expression that is associated to vascular hyperpermeability.
    Gómez R; Simón C; Remohí J; Pellicer A
    Biol Reprod; 2003 Jun; 68(6):2164-71. PubMed ID: 12606463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Administration of low-dose LH induces ovulation and prevents vascular hyperpermeability and vascular endothelial growth factor expression in superovulated rats.
    Gómez R; Lima I; Simón C; Pellicer A
    Reproduction; 2004 Apr; 127(4):483-9. PubMed ID: 15047939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade.
    Gómez R; Simón C; Remohí J; Pellicer A
    Endocrinology; 2002 Nov; 143(11):4339-48. PubMed ID: 12399430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gonadotropin-releasing hormone agonist administration reduced vascular endothelial growth factor (VEGF), VEGF receptors, and vascular permeability of the ovaries of hyperstimulated rats.
    Kitajima Y; Endo T; Manase K; Nishikawa A; Shibuya M; Kudo R
    Fertil Steril; 2004 Mar; 81 Suppl 1():842-9. PubMed ID: 15019818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of gonadotropin-releasing hormone antagonists on the expression of vascular endothelial growth factor and its receptors in a rat model of ovarian hyperstimulation syndrome.
    Tong XM; Zhang SY; Song T; Xu WH; Lin XN; Shu J; Liu L
    Chin Med J (Engl); 2008 Dec; 121(23):2434-9. PubMed ID: 19102964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model.
    Gomez R; Gonzalez-Izquierdo M; Zimmermann RC; Novella-Maestre E; Alonso-Muriel I; Sanchez-Criado J; Remohi J; Simon C; Pellicer A
    Endocrinology; 2006 Nov; 147(11):5400-11. PubMed ID: 16901966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat model of ovarian hyperstimulation syndrome.
    Scotti L; Irusta G; Abramovich D; Tesone M; Parborell F
    Mol Cell Endocrinol; 2011 Mar; 335(2):116-25. PubMed ID: 21238536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes of mRNA expression of vascular endothelial growth factor, angiopoietins and their receptors during the periovulatory period in eCG/hCG-treated immature female rats.
    Miyabayashi K; Shimizu T; Kawauchi C; Sasada H; Sato E
    J Exp Zool A Comp Exp Biol; 2005 Jul; 303(7):590-7. PubMed ID: 15945074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome.
    Soares SR; Gómez R; Simón C; García-Velasco JA; Pellicer A
    Hum Reprod Update; 2008; 14(4):321-33. PubMed ID: 18385260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical detection of transforming growth factor-alpha, epidermal growth factor, and vascular endothelial growth factor expression in hyperstimulated rat ovary.
    Ozcakir HT; Giray SG; Ozbilgin MK; Uyar Y; Lacin S; Caglar H
    Acta Obstet Gynecol Scand; 2005 Sep; 84(9):887-93. PubMed ID: 16097982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signal mechanisms of vascular endothelial growth factor and interleukin-8 in ovarian hyperstimulation syndrome: dopamine targets their common pathways.
    Chen SU; Chou CH; Lin CW; Lee H; Wu JC; Lu HF; Chen CD; Yang YS
    Hum Reprod; 2010 Mar; 25(3):757-67. PubMed ID: 20008399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiology and pathology of ovarian hyperstimulation syndrome.
    Gómez R; Soares SR; Busso C; Garcia-Velasco JA; Simón C; Pellicer A
    Semin Reprod Med; 2010 Nov; 28(6):448-57. PubMed ID: 21082502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine receptor 2 activation inhibits ovarian vascular endothelial growth factor secretion in an ovarian hyperstimulation syndrome (OHSS) animal model: implications for treatment of OHSS with dopamine receptor 2 agonists.
    Ferrero H; García-Pascual CM; Gaytán M; Morales C; Simón C; Gaytán F; Pellicer A; Gómez R
    Fertil Steril; 2014 Nov; 102(5):1468-1476.e1. PubMed ID: 25217874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian vascular endothelial growth factor and vascular endothelial growth factor receptor patterns in reproductive aging.
    Yeh J; Kim BS; Peresie J
    Fertil Steril; 2008 May; 89(5 Suppl):1546-56. PubMed ID: 17889862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The Predictive Role of Vascular Endothelial Growth Factor and Estradiol in Infertile Patients with Ovarian Hyperstimulation Syndrome].
    Wang Q; Yang G; Yang C; Zhan B; Yang R
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Jul; 34(3):565-7. PubMed ID: 12910723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of direct ovarian injection of vascular endothelial growth factor gene fragments on follicular development in immature female rats.
    Shimizu T; Iijima K; Miyabayashi K; Ogawa Y; Miyazaki H; Sasada H; Sato E
    Reproduction; 2007 Nov; 134(5):677-82. PubMed ID: 17965258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Preliminary study on the role of vascular endothelial growth factor in pathogenesis of ovarian hyperstimulation syndrome].
    Zhou C; Yu C; Zhuang G
    Zhonghua Fu Chan Ke Za Zhi; 2001 Nov; 36(11):654-6. PubMed ID: 11930688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of montelukast and cabergoline for prevention of ovarian hyperstimulation syndrome: in an experimental rat model.
    Akman L; Sahin G; Erbas O; Aktug H; Akdogan A; Goker EN; Taskiran D; Tavmergen E
    Gynecol Endocrinol; 2015 May; 31(5):369-73. PubMed ID: 25599748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma levels of soluble vascular endothelial growth factor receptor-1 may determine the onset of early and late ovarian hyperstimulation syndrome.
    Pau E; Alonso-Muriel I; Gómez R; Novella E; Ruiz A; García-Velasco JA; Simón C; Pellicer A
    Hum Reprod; 2006 Jun; 21(6):1453-60. PubMed ID: 16488907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of angiotensin-converting enzyme-inhibiting therapy on the expression of vascular endothelial growth factor in hyperstimulated rat ovary.
    Ozcakir HT; Giray SG; Ozbilgin MK; Inceboz US; Caglar H
    Fertil Steril; 2004 Oct; 82 Suppl 3():1127-32. PubMed ID: 15474085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.